A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Clinical trial NCT06827613 · RECRUITING

Trial details

NCT number: NCT06827613
Sponsor: Marengo Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Triple Negative Locally Advanced Non-resectable Breast Cancer HR+, HER2-, Advanced Breast Cancer

Start date: 2025-03-24
Primary completion: 2027-01-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.